Phase 2
N=40
A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer
Breast Cancer
Bottom Line
View on ClinicalTrials.gov: NCT01201265 ↗Enrolled (actual)
40
Serious AEs
42.5%
Results posted
May 2016
Primary outcome: Primary: Progression-free Survival (PFS) — 255 days
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Bevacizumab (Drug); Carboplatin (Drug); Gemcitabine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Hoffmann-La Roche
- Primary completion
- Apr 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Survival (PFS) |
255 | — |
| SECONDARY Percentage of Participants Achieving an Overall Response |
50.0 | — |
| SECONDARY Percentage of Participants Achieving a Clinical Benefit Response (CBR) |
92.5 | — |
| SECONDARY Time to Progression (TTP) |
269.0 | — |
| SECONDARY Overall Survival (OS) |
475.0 | — |
| SECONDARY Number of Participants With an Adverse Event (AE) |
24 | — |
| SECONDARY Change From Baseline to Cycle 6 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30) |
69.33; -8.82; 71.26; -5.36; 74.58; -4.17 | — |
| SECONDARY Change From Baseline in Systolic Blood Pressure (SBP) |
124.8; -4.6; -4.0; 123.6; 0.2; -6.3 | — |
| SECONDARY Change From Baseline in Diastolic Blood Pressure (DBP) |
80.4; -4.1; -2.0; 78.9; 2.3; 7.5 | — |
Summary
This multicenter study will assess the efficacy and safety of bevacizumab in combination with gemcitabine and cisplatin as first line treatment in participants with triple negative metastatic breast cancer. Participants will receive bevacizumab at a dose of 15 mg/kg intravenously (iv) every 3 weeks, plus gemcitabine (1000 mg/m2 iv) and carboplatin (iv to an area under curve [AUC]=2) on Days 1 and 8 of each 3-week cycle. Anticipated time on study treatment is until disease progression.
Eligibility Criteria
Inclusion Criteria
- Female participants, >/= 18 years of age
- Metastatic breast cancer
- Estrogen receptor-, progesterone- and human epidermal growth factor receptor 2 (HER2)-negative disease
- Treatment-naïve for metastatic breast cancer
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Adequate hematological, renal and liver function
- Patients should have received Anthracyclines and Taxanes in the adjuvant setting
- Women of childbearing potential must agree to use adequate contraception (per institutional standard of care) during treatment and until 6 months after the last administration of investigational products
Exclusion Criteria
- Prior first line treatment for metastatic breast cancer
- Central nervous system (CNS) metastasis
- Uncontrolled hypertension (> 170/95 mmHg)
- Evidence of bleeding diathesis, coagulopathy or hemorrhage at baseline
- Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
- Prior therapy with gemcitabine or carboplatin in the metastatic setting. Participants having received gemcitabine or carboplatin as part of adjuvant therapy are eligible, if recurrence was first documented >6 months after the last exposure to the drug(s)
- Requirement of chronic use of immunosuppressive agents
- HIV, hepatitis B or hepatitis C infection
Data sourced from ClinicalTrials.gov (NCT01201265). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.